Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Mirum Pharmaceuticals
  4. Financial Statements
  5. Income Statement
Mirum Pharmaceuticals logo
Mirum Pharmaceuticals MIRM
$ 80.14 3.04%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Mirum Pharmaceuticals Income Statement 2025-2011 | MIRM

Annual Income Statement Mirum Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 5.45 B 2.41 B 1.09 B 800 M 484 M 473 M 194 M - - - - - - - -

Shares

 50.2 M 47.5 M 40.9 M 33.8 M 30.3 M 26.1 M 11.5 M - - - - - - - -

Historical Prices

 109 50.8 26.8 23.6 15.9 17.5 24.5 - - - - - - - -

Net Income

 -23.4 M -87.9 M -163 M -136 M -84 M -103 M -52.6 M - - - - - - - -

Revenue

 521 M 337 M 186 M 77.1 M 19.1 M - - - - - - - - - -

Operating Income

 -22.1 M -87.6 M -109 M -131 M -173 M -104 M -54.7 M - - - - - - - -

Interest Expense

 2.37 M 1.21 M -2.82 M 365 K -582 K -192 K -21 K - - - - - - - -

EBITDA

 2.11 M -64 M -98.3 M -128 M -173 M -104 M -54.4 M - - - - - - - -

Operating Expenses

 543 M 424 M 296 M 208 M 193 M 104 M 54.7 M - - - - - - - -

General and Administrative Expenses

 257 M 202 M 146 M 89.1 M 59.2 M 22.7 M 11.8 M - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Mirum Pharmaceuticals

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 63.4 M 58.9 M 50.6 M 49.7 M 48.9 M 48.3 M 47.8 M 47.2 M 46.9 M 46.7 M 41.1 M 38.1 M 37.7 M 37 M 34.9 M 32.2 M 31.3 M 30.6 M 30.4 M 30.3 M 30.1 M 29.8 M 25.1 M 25.1 M 24.7 M 22.6 M 18 M 2.55 M 2.52 M 637 K 477 K 637 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

 -67.2 M -790 M 2.9 M -5.86 M -14.7 M - -14.2 M -24.6 M -25.3 M - -23.6 M -74 M -30.1 M - -35.7 M -26.9 M -36.6 M - -47.1 M -43.9 M -50.5 M - -21.5 M -23.3 M -21.3 M - -15.1 M -13.6 M -5.96 M - -67 K -10 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

 176 M 160 M 133 M 128 M 112 M - 90.4 M 77.9 M 69.2 M - 47.7 M 37.5 M 31.6 M - 18.8 M 17.5 M 12.9 M - 5 M 11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

 -42.5 M -789 M 2.6 M -4.99 M -15.2 M - -12.7 M -24.2 M -26.5 M - -25.1 M -24.3 M -27.1 M - -32.9 M -31.4 M -32.7 M - -42.8 M -37.4 M -47.6 M - -21.7 M -23.6 M -22 M - -15.9 M -14 M -6.18 M - -65 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

 -24.2 M - 395 K 86 K 2.11 M - -1.09 M 312 K 1.76 M - 1.32 M -274 K -811 K - -192 K 1.3 M -154 K - -35 K -514 K -16 K - -30 K -56 K -23 K - -5 K 9 K -5 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

 -28.7 M -783 M 8.6 M 911 K -9.13 M - -6.78 M -18.5 M -20.8 M - -22.5 M -23 M -25.8 M - -31.9 M -30.9 M -32.4 M - -42.6 M -37.4 M -47.5 M - -21.5 M -23.5 M -22 M - -15.8 M -14 M -6.18 M - -65 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

 219 M 949 M 130 M 133 M 127 M - 103 M 102 M 95.7 M - 72.9 M 61.8 M 58.7 M - 51.7 M 48.9 M 45.6 M - 47.8 M 48.4 M 47.6 M - 21.7 M 23.6 M 22 M - 15.9 M 14 M 6.18 M - 65 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

 81.5 M 96.3 M 61.9 M 63.3 M 57.7 M - 50.5 M 49.2 M 45.6 M - 36.5 M 32.9 M 30.2 M - 22.5 M 21 M 19.1 M - 17.4 M 13.4 M 9.48 M - 5.73 M 5.04 M 4.69 M - 3.71 M 2.44 M 1.32 M - 62 K 10 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Mirum Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
 		- - - russiaRussia
ММЦБ ММЦБ
GEMA
 		- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
 		- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
 		- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
 		- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
 		- - - russiaRussia
Промомед Промомед
PRMD
 		- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
 		- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
 		- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
 		- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
 		- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
 		- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
 		- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
 		- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
 		$ 1.12 0.88 % $ 7.05 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
 		$ 1.04 1.36 % $ 104 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
 		$ 11.8 2.51 % $ 3.52 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
 		$ 55.9 0.22 % $ 7.48 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
 		$ 54.68 1.65 % $ 10.5 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
 		$ 27.53 3.93 % $ 1.83 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
 		$ 3.63 0.64 % $ 44.3 M israelIsrael
Jaguar Health Jaguar Health
JAGX
 		$ 3.53 9.81 % $ 8.23 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
 		$ 2.62 3.05 % $ 206 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
 		$ 21.78 7.39 % $ 1.25 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
 		$ 24.17 5.8 % $ 1.43 B usaUSA
Xencor Xencor
XNCR
 		$ 22.85 2.61 % $ 1.7 B usaUSA
Annexon Annexon
ANNX
 		$ 3.41 1.09 % $ 529 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
 		$ 1.76 0.54 % $ 2.9 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
 		$ 113.07 0.03 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
 		$ 13.28 1.16 % $ 16 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
 		$ 9.28 5.1 % $ 746 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
 		$ 499.74 0.08 % $ 128 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
 		$ 225.25 0.42 % $ 13.7 B danmarkDanmark
Axon Enterprise Axon Enterprise
AXON
 		$ 390.29 2.15 % $ 30.5 B usaUSA
AbbVie AbbVie
ABBV
 		$ 285.42 0.71 % $ 505 B usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
 		$ 1.72 2.35 % $ 97.8 M usaUSA
Altimmune Altimmune
ALT
 		$ 2.2 2.16 % $ 194 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
 		$ 4.22 2.39 % $ 809 M canadaCanada
Oncternal Therapeutics Oncternal Therapeutics
ONCT
 		- -24.12 % $ 1.56 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
 		$ 11.84 0.87 % $ 1.06 B usaUSA
Seagen Seagen
SGEN
 		- - $ 42.2 B usaUSA
Codexis Codexis
CDXS
 		$ 1.24 5.43 % $ 108 M usaUSA
Cullinan Management Cullinan Management
CGEM
 		$ 12.93 2.64 % $ 779 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
 		$ 1.96 4.0 % $ 183 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
 		$ 1.14 0.84 % $ 2.97 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
 		$ 11.32 0.17 % $ 4.7 B irlandaIrlanda
Alpine Immune Sciences Alpine Immune Sciences
ALPN
 		- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		- - $ 26.5 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
 		$ 1.02 0.49 % $ 11.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
 		$ 3.28 3.25 % $ 402 M usaUSA